Fortis stock holds steady as Supreme Court move adds legal overhang

Published on 09/19/2026 at 21:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fortis stock closed at INR 886.00 on the NSE on September 18, 2026, about 19 percent below its 52-week high of INR 1,104.30. A pending Supreme Court challenge to a forensic audit order keeps legal risks in focus for Fortis Healthcare investors.

Fortis, INE061F01013, Illustration mit AI erstellt.

Fortis Healthcare Limited stock (ISIN INE061F01013) finished trading at INR 886.00 on the National Stock Exchange of India as of September 18, 2026, virtually unchanged from its previous close and leaving the shares well below their recent 52-week peak of INR 1,104.30.

Stock trades below 52-week high

According to data from an Indian stock portal on September 19, 2026, Fortis Healthcare shares last traded at INR 886.00, with the previous close at INR 886.10 and a one-day move of about minus 0.02 percent as of the latest update for September 18, 2026.

Portal data show that Fortis Healthcare’s 52-week high stands at INR 1,104.30, while the 52-week low is INR 766.80 as of September 19, 2026, meaning the current price is roughly 19.8 percent below the high and 15.6 percent above the low for the period.

Market capitalization and valuation metrics

As of September 18, 2026, Fortis Healthcare’s market capitalization is reported at INR 66,889.30 crore, placing the company firmly among India’s larger listed healthcare providers by equity value.

The same price overview for September 19, 2026 indicates that the shares trade on a price-earnings ratio of 63.8 and a price-to-book ratio of 6.6, illustrating that investors continue to assign a premium valuation to Fortis Healthcare relative to book equity.

Recent operating figures in focus

A performance snapshot labeled for September 25 in crore rupees shows Fortis Healthcare reporting revenue of INR 455.81 crore and net income of INR 125.09 crore for that period, corresponding to a net profit margin of 27.44 percent.

In a separate set of figures for another recent period, the company is shown with earnings per share of minus INR 0.18, EBITDA of INR 233.22 crore and a net profit margin of minus 1.53 percent, highlighting that profitability can vary significantly across reporting intervals.

Legal proceedings add risk backdrop

As ANI News reported in an update dated September 19, 2026, the Delhi High Court has ordered a forensic audit into the dissipation of Fortis Healthcare shares in connection with the Daiichi Sankyo award case valued at INR 5,300 crore.

The same legal topic is summarized in a health-sector newsletter, which notes that Fortis Healthcare has moved the Supreme Court of India against the forensic audit order, indicating that the company is actively contesting elements of the High Court’s directions.

What the numbers mean for Fortis stock

For investors, the combination of a rich valuation, represented by a price-earnings multiple above 60 as of September 19, 2026, and the legal uncertainty around the forensic audit of historic Fortis Healthcare share dealings forms a key part of the current risk-reward profile.

At a price of INR 886.00 on September 18, 2026, Fortis stock trades noticeably below its 52-week high of INR 1,104.30, yet still above the 52-week low of INR 766.80, suggesting that the market has cooled from earlier peaks but continues to price in meaningful expectations for the company’s healthcare operations and potential earnings power.

Closing price and trading venue

Fortis Healthcare stock is primarily listed on the National Stock Exchange of India under the ticker FORTIS, where it closed at INR 886.00 on September 18, 2026, with a marginal day-on-day decline of about 0.01 percent based on the stated prior close.